Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings

Akinci, Baris; Subauste, Angela; Ajluni, Nevin; Esfandiari, Nazanene; Meral, Rasimcan; Neidert, Adam; Eraslan, Akin; Hench, Rita; Rus, Diana; Mckenna, Barbara; Hussain, Hero; Chenevert, Thomas; Tayeh, Marwan; Rupani, Amit; Innis, Jeffrey; Mantzoros, Christos; Conjeevaram, Hari; Burant, Charles; Oral, Elif

doi:10.1016/j.medj.2021.04.001

Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings

Akinci B., Subauste A., Ajluni N., Esfandiari N. H., Meral R., Neidert A. H., ...More

MED, vol.2, no.7, pp.814-842, 2021 (ESCI, Scopus)

Publication Type: Article / Article
Volume: 2 Issue: 7
Publication Date: 2021
Doi Number: 10.1016/j.medj.2021.04.001
Journal Name: MED
Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
Page Numbers: pp.814-842
Open Archive Collection: AVESIS Open Access Collection
Dokuz Eylül University Affiliated: No

Abstract

Background: Recombinant leptin therapy reverses nonalcoholic steatohepatitis (NASH) in leptin-deficient lipodystrophy. We inquired if leptin therapy would improve NASH in more common forms of this heterogeneous condition.